Pharmaceutical

Allied is committed to developing cutting-edge technology that focuses on treating mental illness, specifically targeted at PTSD and other forms of mental trauma for Veterans and First Responders.

Pharma Development Model

Allied Corp. Files First US Provisional Patent Application for Cannabinoid and Terpenoid Pharmaceutical Compositions and Methods for Treating Post-Traumatic Stress Disorder

On September 23, 2019, Allied announced the filing of its first United States Provisional Patent Application for Cannabinoid and Terpenoid Pharmaceutical Compositions and Methods for Treating Post-Traumatic Stress Disorder (PTSD).

This marks the first of a series of proposed filings, along with recent trademark filings, as part of the Company’s Intellectual Property and Pharma Development (IP&PD) Strategy. This Pharma Development Strategy includes serving those suffering from mental health issues, with a particular focus on those suffering from symptoms related to PTSD.

The products developed under the Company’s IP&PD strategy are initially geared towards veterans and first responders and will further be available to anyone else suffering from symptoms related to PTSD. These products will be made available for sale under Allied’s recently launched natural health hemp-derived retail product line, TACTICAL RELIEF™.

“We are very excited to begin taking the strategic steps to developing and protecting our IP&PD strategy in the United States and around the world. Allied is committed to the development of a thoughtful and strategic Intellectual Property portfolio that is strengthened internationally by this filing.”
David Weinkauf, VP Pharma Development
“We are very excited to begin taking the strategic steps to developing and protecting our IP&PD strategy in the United States and around the world. Allied is committed to the development of a thoughtful and strategic Intellectual Property portfolio that is strengthened internationally by this filing.”
David Weinkauf, VP Pharma Development
“Currently, there are approximately 8 million people in the United States alone who suffer from symptoms related to PTSD. Although there are certain cognitive therapies that have proven to be helpful, there is no pharmaceutical drug that has an indication for this disease target. PTSD is a disorder that not only affects the person suffering, but his/her family and community as well. Through this patent filing, we have now taken the first step in our pharma development plan, as well as, protected our medical formulation that is focused on this disease target.”
Calum Hughes, CEO

Pre-Clinical

  • Research Services Agreement under negotiation
  • Pre-Clinical animal model currently under way
  • On September 23, 2019, Allied announced the filing of its first United States Provisional Patent Application for Cannabinoid and Terpenoid Pharmaceutical Compositions and Methods for Treating Post-Traumatic Stress Disorder (PTSD).
  • Intellectual property is owned by Allied Corp

Clinical

  • End stage discussions with large clinical research centre
  • PHASE 1 Clinical Trial planned for Q4 2019
  • After PHASE 1 data set has been completed, we intend to license to Big Pharma

Partnership With Evoke

Allied Corp will utilize Evoke’s eVox System to generate an objective and automated report for clinicians and researchers to use as a baseline and to aid diagnosis and facilitate treatment planning for patients living with PTSD.
  • Evoke supports Allied’s existing and planned clinical trials by providing pre- and post- treatment measurements of patients’ cognitive functions. The eVox system is deployed for these efforts and Evoke would be able to train staff on how to operate the device to collect data.

  • Allied and Evoke will work together to expand their existing marketing efforts with respect to Veterans, PTSD patients and new markets (e.g. Pain management). Evoke has the capability to provide objective measures of PTSD and chronic pain that could be customized for the specific application.

  • Allied can develop a commercial package that pairs it’s therapy products with a pre – and post – treatment eVox assessment. This will help Allied differentiate its products to a clinician target market.

Sign up to our newsletter and get first access to the latest investor news, events, and other important information related to Allied Health.

Keep Informed